As earnings season ramps up next week, a select group of stocks could exceed Wall Street’s estimates and outperform again, if history is any guide. Next week is a doozy for the second-quarter earnings season, with 98 companies in the S & P 500 — about 20% of the index — scheduled to report their latest results. The week is led by such market stalwarts as Alphabet , Tesla and General Motors , but will also notable for telecom and defense stocks. Stocks can often rise if they post earnings or revenue surprises that beat analysts’ expectations. With that history in mind, CNBC Pro screened Bespoke Investor Group data to find stocks that tend to top Street forecasts and then rally afterward. Specifically, the companies below have beaten earnings per share estimates at least 75% of the time and average a gain of 1.5% or more the first day after posting their latest financials. Fast-casual Mexican restaurant chain Chipotle Mexican Grill reports earnings next Wednesday . The Southern California-based company has historically topped analysts’ earnings estimates 78% of the time, on average has risen 1.6% following the earnings report. Ahead of Chipotle’s second-quarter earnings release, Deutsche Bank reiterated its buy rating on the $73 billion stock on Tuesday. “Sentiment on CMG has improved over the last several weeks as underlying trends accelerated exiting 2Q, and continued momentum should support upside to 2H estimates,” analyst Lauren Silberman wrote in a report. “We expect 2Q fundamentals to be a trough with an improving setup from here, and together with current valuation, believe CMG offers a favorable risk/reward.” Shares of Chipotle Mexican Grill have slipped about 11% this year. Deutsche Bank’s $70 price target implies potential upside of about 31% for Chipotle over the next 12 months. Intuitive Surgical is another company reporting next week with a history of beating earnings expectations. The medical device maker has topped bottom-line estimates 88% of the time, with its stock averaging a 2.5% gain on days its results are released. Shares are about flat in 2025. However, they have gained nearly 7% over the past three months as investors grow optimistic about the company’s Da Vinci 5 robotic surgery system. “We often get asked about what new procedures DV5 will unlock and thus grow ISRG’s already massive [total addressable market]. While we do believe DV5 will bring soft tissue robotics into uncharted waters over time, we also think some investors may be overlooking ISRG’s endoluminal robot (Ion) and VC (venture capital) portfolio, which we believe could also expand the company’s TAM in the future,” Piper Sandler analyst Adam Maeder said in a recent note.
